Bruce Larson1,2, Amir Shroufi3, Charles Muthoga4, Rita Oladele5, Radha Rajasingham6, Alexander Jordan7, Joseph N Jarvis4,8, Tom M Chiller7, Nelesh P Govender9,10. 1. Global Health, Boston University School of Public Health, Boston, MA, 02118, USA. 2. Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. CDC Foundation, Cape Town, South Africa. 4. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 5. College of Medicine, Univerity of Lagos, Lagos, Nigeria. 6. Division of Infectious Diseases & International Medicine, University of Minnesota, Minneapolis, Minnesota, USA. 7. Mycotic Diseases Branch, Centers for Disease Controls and Prevention, Atlanta, Georgia, USA. 8. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. 9. National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. 10. University of Witwatersrand, Johannesburg, South Africa.
Abstract
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create opportunities to reduce CM treatment costs compared to the current standard treatment in low- and middle-income countries. Methods: We developed an Excel-based cost model to estimate health system treatment costs for CM over a two-week induction phase for multiple treatment combinations, newly feasible with improved access to flucytosine and AmB-L. CM treatment costs include medications, laboratory tests and other hospital-based costs (bed-day costs and healthcare worker time). We report results from applying the model using country-specific information for South Africa, Uganda, Nigeria, and Botswana. Results: A 14-day induction-phase of seven days of inpatient AmB-D with flucytosine, followed by seven days of high-dose fluconazole as an outpatient, will cost health systems less than a 14-day hospital stay with AmB-D and fluconazole. If daily AmB-L replaces AmB-D for those with baseline renal dysfunction, with a cost of $50 or less per 50 mg vial, incremental costs would still be less than the AmB-D with fluconazole regimen. Simple oral combinations (e.g., seven days of flucytosine with fluconazole as an inpatient) are practical when AmB-D is not available, and treatment costs would remain less than the current standard treatment. Conclusions: Improved access to and lower prices for flucytosine and AmB-L create opportunities for improving CM treatment regimens. An induction regimen of flucytosine and AmB-D for seven days is less costly than standard care in the settings studied here. As this regimen has also been shown to be more effective than current standard care, countries should prioritize scaling up flucytosine access. The cost of AmB-L based regimens is highly dependent on the price of AmB-L, which currently remains unclear. Copyright:
Introduction: Access to and the cost of induction treatment for cryptococcal meningitis (CM) is rapidly changing. The newly-announced price for flucytosine ($0.75 per 500 mg pill) and possibly lower prices for liposomal amphotericin B (AmB-L) create opportunities to reduce CM treatment costs compared to the current standard treatment in low- and middle-income countries. Methods: We developed an Excel-based cost model to estimate health system treatment costs for CM over a two-week induction phase for multiple treatment combinations, newly feasible with improved access to flucytosine and AmB-L. CM treatment costs include medications, laboratory tests and other hospital-based costs (bed-day costs and healthcare worker time). We report results from applying the model using country-specific information for South Africa, Uganda, Nigeria, and Botswana. Results: A 14-day induction-phase of seven days of inpatient AmB-D with flucytosine, followed by seven days of high-dose fluconazole as an outpatient, will cost health systems less than a 14-day hospital stay with AmB-D and fluconazole. If daily AmB-L replaces AmB-D for those with baseline renal dysfunction, with a cost of $50 or less per 50 mg vial, incremental costs would still be less than the AmB-D with fluconazole regimen. Simple oral combinations (e.g., seven days of flucytosine with fluconazole as an inpatient) are practical when AmB-D is not available, and treatment costs would remain less than the current standard treatment. Conclusions: Improved access to and lower prices for flucytosine and AmB-L create opportunities for improving CM treatment regimens. An induction regimen of flucytosine and AmB-D for seven days is less costly than standard care in the settings studied here. As this regimen has also been shown to be more effective than current standard care, countries should prioritize scaling up flucytosine access. The cost of AmB-L based regimens is highly dependent on the price of AmB-L, which currently remains unclear. Copyright:
Authors: Bruce Larson; Amir Shroufi; Charles Muthoga; Rita Oladele; Radha Rajasingham; Alexander Jordan; Joseph N Jarvis; Tom M Chiller; Nelesh P Govender Journal: Wellcome Open Res Date: 2022-06-20
Authors: Jacob Bor; Matthew P Fox; Sydney Rosen; Atheendar Venkataramani; Frank Tanser; Deenan Pillay; Till Bärnighausen Journal: PLoS Med Date: 2017-11-28 Impact factor: 11.613
Authors: Angela Loyse; Jessica Burry; Jennifer Cohn; Nathan Ford; Tom Chiller; Isabela Ribeiro; Sinata Koulla-Shiro; Janneth Mghamba; Angela Ramadhani; Rose Nyirenda; Sani H Aliyu; Douglas Wilson; Thuy Le; Rita Oladele; Sokoine Lesikari; Conrad Muzoora; Newton Kalata; Elvis Temfack; Yacouba Mapoure; Victor Sini; Duncan Chanda; Meshack Shimwela; Shabir Lakhi; Jonathon Ngoma; Lilian Gondwe-Chunda; Chase Perfect; Amir Shroufi; Isabelle Andrieux-Meyer; Adrienne Chan; Charlotte Schutz; Mina Hosseinipour; Charles Van der Horst; Jeffrey D Klausner; David R Boulware; Robert Heyderman; David Lalloo; Jeremy Day; Joseph N Jarvis; Marcio Rodrigues; Shabbar Jaffar; David Denning; Chantal Migone; Megan Doherty; Olivier Lortholary; Françoise Dromer; Muirgen Stack; Síle F Molloy; Tihana Bicanic; Joep van Oosterhout; Peter Mwaba; Cecilia Kanyama; Charles Kouanfack; Sayoki Mfinanga; Nelesh Govender; Thomas S Harrison Journal: Lancet Infect Dis Date: 2018-10-18 Impact factor: 25.071
Authors: William Hope; Neil R H Stone; Adam Johnson; Laura McEntee; Nicola Farrington; Anahi Santoro-Castelazo; Xuan Liu; Anita Lucaci; Margaret Hughes; Jason D Oliver; Charles Giamberardino; Sayoki Mfinanga; Thomas S Harrison; John R Perfect; Tihana Bicanic Journal: mBio Date: 2019-12-03 Impact factor: 7.867
Authors: Nelesh P Govender; Graeme Meintjes; Phetho Mangena; Jeremy Nel; Samantha Potgieter; Denasha Reddy; Helena Rabie; Douglas Wilson; John Black; David Boulware; Tom Boyles; Tom Chiller; Halima Dawood; Sipho Dlamini; Thomas S Harrison; Prudence Ive; Joseph Jarvis; Alan Karstaedt; Matamela C Madua; Colin Menezes; Mahomed-Yunus S Moosa; Zaaheera Motlekar; Amir Shroufi; Sarah Lynn Stacey; Merika Tsitsi; Gilles van Cutsem; Ebrahim Variava; Michelle Venter; Rachel Wake Journal: South Afr J HIV Med Date: 2019-11-08 Impact factor: 2.744
Authors: Bruce Larson; Amir Shroufi; Charles Muthoga; Rita Oladele; Radha Rajasingham; Alexander Jordan; Joseph N Jarvis; Tom M Chiller; Nelesh P Govender Journal: Wellcome Open Res Date: 2022-06-20